World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
30205
World Ranking
1484
National Ranking
58

Medicine

D-Index
82
Citations
30237
World Ranking
15945
National Ranking
517

Olivier Lambotte publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Olivier Lambotte sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 347 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Olivier Lambotte D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Olivier Lambotte sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 82 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Olivier Lambotte is affiliated with the University of Paris-Saclay in France and has a research focus centered in the field of Medicine, with a specialization in Oncology, Immunology, Virology, Infectious Diseases, and Molecular Biology.

Their research covers a variety of topics including:

  • Cancer Immunotherapy and Biomarkers
  • HIV Research and Treatment
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • HIV-related health complications and treatments
  • HIV/AIDS drug development and treatment

Olivier Lambotte has contributed to several frequent publication venues, which include:

  • European Journal of Cancer
  • La Revue de Médecine Interne
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Frontiers in Immunology
  • Nature Communications

Among notable recent papers in their field, these are examples reflecting broader topics in clinical medicine and immunology:

  • Immune-related adverse events of checkpoint inhibitors, 2020, Nature Reviews Disease Primers
  • Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia, 2020, JAMA Internal Medicine
  • Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021, 2021, Nature Medicine
  • Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial, 2021, The Lancet Respiratory Medicine
  • EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors, 2020, Annals of the Rheumatic Diseases

Frequent co-authors collaborating with Olivier Lambotte include:

  • Nicolas Noël
  • Jean-Marie Michot
  • Cécile Goujard
  • Stéphane Champiat
  • Xavier Mariette

Best Publications

  • Microbial translocation is a cause of systemic immune activation in chronic HIV infection

    Jason M. Brenchley;David A. Price;Timothy W. Schacker;Tedi E. Asher

  • Immune-related adverse events with immune checkpoint blockade: a comprehensive review

    J.M. Michot;C. Bigenwald;S. Champiat;M. Collins

  • Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.

    Laurence Fardet;Lionel Galicier;Olivier Lambotte;Christophe Marzac

  • Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

    Asier Sáez-Cirión;Charline Bacchus;Laurent Hocqueloux;Véronique Avettand-Fenoel

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir

  • HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

    Asier Sáez-Cirión;Christine Lacabaratz;Olivier Lambotte;Pierre Versmisse

  • Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

    Eleonora De Martin;Jean-Marie Michot;Barbara Papouin;Stéphane Champiat

  • Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases

    JE Gottenberg;L Guillevin;O Lambotte;B Combe

  • HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

    Olivier Lambotte;Faroudy Boufassa;Yoann Madec;Ahn Nguyen

  • Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

    Benjamin Terrier;Zahir Amoura;Philippe Ravaud;Eric Hachulla

  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

    Olivier Lambotte;Guido Ferrari;Christiane Moog;Nicole L Yates

  • Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 Patients

    Sébastien Rivière;Lionel Galicier;Paul Coppo;Christophe Marzac

  • Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

    Audrey Simonaggio;Jean Marie Michot;Anne Laure Voisin;Jérome Le Pavec

  • The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease.

    Georgia Malamut;Virginie Verkarre;Felipe Suarez;Jean-François Viallard

  • Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

    François-Xavier Danlos;Anne-Laure Voisin;Valérie Dyevre;Jean-Marie Michot

  • Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

    Alice Tison;Gilles Quéré;Laurent Misery;Elisa Funck-Brentano

  • Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

    Sophie Reuse;Miriam Calao;Kabamba Kabeya;Allan Guiguen

  • Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses

    Asier Sáez-Cirión;Martine Sinet;So Youn Shin;Alejandra Urrutia

  • Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy.

    O Lambotte;Y Taoufik;M G de Goër;C Wallon

  • Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

    Pierre-Louis Tharaux;Gilles Pialoux;Arthur Pavot;Xavier Mariette

Frequent Co-Authors

Cécile Goujard
Cécile Goujard University of Paris-Saclay
Faroudy Boufassa
Faroudy Boufassa University of Paris-Saclay
Jean-François Delfraissy
Jean-François Delfraissy National Ethical Consultative Committee for Life Sciences and Health
Aurélien Marabelle
Aurélien Marabelle Institut Gustave Roussy
Alain Venet
Alain Venet Grenoble Alpes University
Lionel Galicier
Lionel Galicier Université Paris Cité
Christine Rouzioux
Christine Rouzioux Necker-Enfants Malades Hospital
Laurence Meyer
Laurence Meyer University of Paris-Saclay
Gianfranco Pancino
Gianfranco Pancino Institut Pasteur
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career opportunities. Many professionals consider bridging their expertise by enrolling in programs like the cheapest online PMHNP certificate programs. These affordable paths help nurses specialize in psychiatric mental health, complementing immunological knowledge in patient care.

Understanding salary trends is also crucial when selecting a career path. The highest paid DNP specialties highlight how advanced practice roles can be financially rewarding, motivating students to align their education with growing fields in nursing and healthcare.

For those already certified as a Family Nurse Practitioner (FNP), transitioning to more specialized roles such as an acute care nurse practitioner is feasible. Informative guides like FNP to ACNP detail the steps required for advancing clinical skills and expanding career horizons.

Accelerated educational options exist for registered nurses aiming to fast-track their careers. Programs such as highlighted in accelerated RN to NP programs offer intensive online learning tailored for working professionals seeking nurse practitioner roles.

Exploring these pathways alongside a foundation in Immunology can enhance both clinical expertise and professional growth in the evolving healthcare landscape.

Best Scientists Citing Olivier Lambotte

Trending Scientists

Recently Published Articles